Aurobindo Pharma Limited (NSE:AUROPHARMA)
India
· Delayed Price · Currency is INR 1,281.50
+34.20 (2.74%)
Mar 10, 2026, 2:10 PM IST
Aurobindo Pharma Ratios and Metrics
Market cap in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 9, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | 2020 - 2016 |
| Market Capitalization | 724,434 | 674,020 | 637,941 | 303,575 | 391,729 | 516,388 | Upgrade
|
| Market Cap Growth | 10.25% | 5.66% | 110.14% | -22.50% | -24.14% | 113.31% | Upgrade
|
| Enterprise Value | 713,382 | 689,676 | 632,994 | 283,996 | 394,408 | 532,915 | Upgrade
|
| Last Close Price | 1247.30 | 1156.16 | 1084.68 | 513.88 | 653.35 | 855.63 | Upgrade
|
| PE Ratio | 20.78 | 19.34 | 20.11 | 15.75 | 14.79 | 9.68 | Upgrade
|
| Forward PE | 17.36 | 15.91 | 17.77 | 12.19 | 12.83 | 14.88 | Upgrade
|
| PS Ratio | 2.18 | 2.13 | 2.20 | 1.22 | 1.67 | 2.08 | Upgrade
|
| PB Ratio | 2.07 | 2.07 | 2.14 | 1.13 | 1.59 | 2.36 | Upgrade
|
| P/TBV Ratio | 2.37 | 2.36 | 2.46 | 1.31 | 1.85 | 2.73 | Upgrade
|
| P/FCF Ratio | - | 34.45 | - | - | 13.22 | 27.31 | Upgrade
|
| P/OCF Ratio | - | 17.17 | 26.20 | 12.72 | 7.81 | 15.51 | Upgrade
|
| PEG Ratio | 1.39 | 1.36 | 0.78 | 1.63 | 2.09 | 1.35 | Upgrade
|
| EV/Sales Ratio | 2.15 | 2.17 | 2.18 | 1.14 | 1.68 | 2.15 | Upgrade
|
| EV/EBITDA Ratio | 10.60 | 10.64 | 10.98 | 7.81 | 9.15 | 9.88 | Upgrade
|
| EV/EBIT Ratio | 13.85 | 13.71 | 14.41 | 11.31 | 11.93 | 11.97 | Upgrade
|
| EV/FCF Ratio | - | 35.25 | - | - | 13.31 | 28.18 | Upgrade
|
| Debt / Equity Ratio | 0.22 | 0.25 | 0.22 | 0.20 | 0.12 | 0.24 | Upgrade
|
| Debt / EBITDA Ratio | 1.15 | 1.26 | 1.14 | 1.43 | 0.65 | 0.97 | Upgrade
|
| Debt / FCF Ratio | - | 4.22 | - | - | 0.96 | 2.82 | Upgrade
|
| Net Debt / Equity Ratio | -0.03 | 0.00 | 0.01 | -0.04 | -0.07 | -0.01 | Upgrade
|
| Net Debt / EBITDA Ratio | -0.16 | 0.01 | 0.06 | -0.26 | -0.40 | -0.05 | Upgrade
|
| Net Debt / FCF Ratio | - | 0.03 | -0.93 | 55.51 | -0.58 | -0.15 | Upgrade
|
| Asset Turnover | - | 0.67 | 0.68 | 0.67 | 0.69 | 0.79 | Upgrade
|
| Inventory Turnover | - | 1.33 | 1.42 | 1.45 | 1.26 | 1.22 | Upgrade
|
| Quick Ratio | - | 0.99 | 0.96 | 0.98 | 1.10 | 0.90 | Upgrade
|
| Current Ratio | - | 1.85 | 1.98 | 1.88 | 2.22 | 1.86 | Upgrade
|
| Return on Equity (ROE) | - | 11.15% | 11.18% | 7.50% | 11.39% | 27.53% | Upgrade
|
| Return on Assets (ROA) | - | 6.63% | 6.46% | 4.25% | 6.10% | 8.87% | Upgrade
|
| Return on Invested Capital (ROIC) | 10.32% | 11.01% | 11.33% | 7.60% | 11.66% | 15.57% | Upgrade
|
| Return on Capital Employed (ROCE) | - | 14.30% | 13.40% | 8.80% | 12.80% | 19.20% | Upgrade
|
| Earnings Yield | 4.81% | 5.17% | 4.97% | 6.35% | 6.76% | 10.33% | Upgrade
|
| FCF Yield | - | 2.90% | -0.54% | -0.06% | 7.56% | 3.66% | Upgrade
|
| Dividend Yield | 0.65% | - | 0.41% | 0.58% | 1.38% | 0.47% | Upgrade
|
| Payout Ratio | - | 0.03% | 8.31% | 22.80% | 9.96% | 4.39% | Upgrade
|
| Buyback Yield / Dilution | 0.50% | 0.52% | - | - | - | - | Upgrade
|
| Total Shareholder Return | 1.15% | 0.52% | 0.41% | 0.58% | 1.38% | 0.47% | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.